Vicasinabin (RG7774) is the potent agonist of CB2). Vicasinabin has the potential for the research of human diseases including chronic pain, atherosclerosis, regulation of bone mass, neuroinflammation, and other related diseases (extracted from patent US20130116236A1)[1].
[1]. Jean-Michel Adam, et al. Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives. Patent US20130116236A1.
















